Trinity Biotech plc develops, manufactures, and markets in vitro diagnostic products across clinical laboratory and point-of-care segments. The company's product portfolio spans infectious disease testing, including serology assays for sexually transmitted infections, viral pathogens such as SARS-CoV-2 and Epstein-Barr virus, and hemoglobin A1c measurement for diabetes diagnosis and monitoring. The company also offers laboratory-testing services for autoimmune disorders including Sjögren's syndrome, lupus, rheumatoid arthritis, and celiac disease, as well as reagent products for liver, kidney, and hemolytic anemia diagnostics. Products are available in multiple assay formats including immunofluorescence, ELISA, western blot, and line immunoassay.
The company distributes its offerings through direct sales to public health authorities and clinical reference laboratories, supplemented by a network of independent distributors and strategic partners across the Americas, Europe, Africa, and Asia. Trinity Biotech operates approximately 401 full-time employees and is headquartered in Bray, Ireland, with incorporation in Ireland. The company maintains a collaboration agreement focused on epigenetic liquid biopsy testing for prostate cancer risk assessment.
No 10-K filings found.